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Abstract
Verification of candidate biomarkers relies upon specific, quantitative assays optimized for
selective detection of target proteins, and is increasingly viewed as a critical step in the discovery
pipeline that bridges unbiased biomarker discovery to preclinical validation. Although individual
laboratories have demonstrated that multiple reaction monitoring (MRM) coupled with isotope
dilution mass spectrometry can quantify candidate protein biomarkers in plasma, reproducibility
and transferability of these assays between laboratories have not been demonstrated. We describe
a multilaboratory study to assess reproducibility, recovery, linear dynamic range and limits of
detection and quantification of multiplexed, MRM-based assays, conducted by NCI-CPTAC.
Using common materials and standardized protocols, we demonstrate that these assays can be
highly reproducible within and across laboratories and instrument platforms, and are sensitive to
low µg/ml protein concentrations in unfractionated plasma. We provide data and benchmarks
against which individual laboratories can compare their performance and evaluate new
technologies for biomarker verification in plasma.
Proteomic technologies based on mass spectrometry (MS) have emerged as preferred
components of a strategy for discovery of diagnostic, prognostic and therapeutic protein
biomarkers. Because of the stochastic sampling of proteomes in unbiased analyses and the
associated high false-discovery rate, tens to hundreds of potential biomarkers are often
reported in discovery studies. Those few that will ultimately show sufficient sensitivity and
specificity for a given medical condition must thus be culled from lengthy lists of candidates
— a particularly challenging aspect of the biomarker-development pipeline and currently its
main limiting step. In this context, it is highly desirable to verify, by more targeted
quantitative methods, the levels of candidate biomarkers in body fluids, cells, tissues or
organs from healthy individuals and affected patients in large enough sample numbers to
confirm statistically relevant differences1,2. Verification of novel biomarkers has relied
primarily on the use of sensitive, specific, high-throughput immunoassays, whose
development depends critically on the availability of suitable well-characterized antibodies.
However, antibody reagents of sufficient specificity and sensitivity to assay novel protein
biomarkers in plasma are generally not available. The high cost and long development time
required to generate high-quality immunoassay reagents, as well as technical limitations in
multiplexing immunoassays for panels of biomarkers, is strong motivation to develop more
straightforward quantitative approaches exploiting the sensitivity and molecular specificity
of mass spectrometry.
Recently, multiple reaction monitoring (MRM) coupled with stable isotope dilution (SID)-
MS for direct quantification of proteins in cell lysates as well as human plasma and serum
has been shown to have considerable promise3–10. With SID-MRM-MS, up to tens of
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candidate proteins can be nearly simultaneously targeted and quantified in plasma by
detecting ‘signature’ peptides, those that are diagnostic for each protein8,9. These reports
suggest that this technology may be suitable for use in preclinical studies to rapidly screen
large numbers of candidate protein biomarkers in the hundreds of patient samples necessary
for verification2. Widespread acceptance and adoption of SID-MRM-MS methods are
presently limited because the reproducibility and transferability of protein-based MRM
assays across different instrument platforms and laboratories have yet to be demonstrated.
To address this issue, the Clinical Proteomic Technology Assessment for Cancer network of
the National Cancer Institute (NCI-CPTAC) evaluated intra- and interlaboratory analytical
performance of SID-MRM-MS assays for quantifying seven target proteins added to human
plasma. Our study demonstrates that targeted, quantitative and multiplexed MS-based assays
can be rapidly configured and deployed in multiple laboratories to reproducibly measure
proteins present at moderate to high abundance (>2 µg/ml), with a linear dynamic range
spanning three orders of magnitude, in nondepleted, nonfractionated plasma, the most
complex of all biological matrices.
RESULTS
Study design
A series of interrelated studies was designed to assess the reproducibility and quantitative
characteristics of MRM assays across the eight participating laboratories for measurement of
peptides and proteins in the context of human plasma. The studies (I–III) sequentially
introduced additional sources of variability in sample preparation and instrumental analyses,
thereby enabling assessment of their impact on the quantitative measurements (Fig. 1 and
Table 1). In studies I and II, samples were prepared centrally at the National Institute of
Standards and Technology (NIST) and then distributed to the laboratories for SID-MRM-
MS analyses. Variability arising from digestion of the target proteins was bypassed in study
I by spiking a common pool of reduced, alkylated and trypsin-digested plasma with 11
unlabeled signature peptides derived from the target proteins at nine different
concentrations. In study II, seven target proteins were digested separately, mixed with a
stock solution of labeled peptides and digested plasma, then diluted serially with a labeled
peptide/digested plasma stock to generate the same nine concentrations. Study III, which
encompassed nearly all potential sources of analytical variability normally encountered,
most closely simulated an actual biomarker verification experiment. Specifically, we
produced an equimolar mixture of the same seven proteins in undiluted plasma at the same
nine concentrations. Then, aliquots were distributed to the eight sites where the samples
were denatured, reduced, alkylated, digested and desalted according to a standard operating
procedure (SOP, Supplementary Methods). Labeled internal standard peptides were added
immediately before SID-MRM-MS analysis. In all three studies, four technical replicates
were performed at each concentration; in study III, three independent process replicates
(IIIa, IIIb and IIIc) assessed intralaboratory and interlaboratory variability.
The MRM assay configuration (including gradient development, selection of MRM analyte
transitions for each signature peptide and general instrument settings) was performed at a
single site using a nanoflow liquid chromatography (LC) (Eksigent NanoLC-2D) system
coupled to a hybrid triple quadrupole/linear ion trap (AB/MDS Analytical Technologies
4000 QTRAP) mass spectrometer. These methods and parameters were transferred to all
laboratories regardless of instrument platform to minimize variability arising from data
acquisition (Online Methods and Supplementary Methods). All sites monitored three
transitions per peptide, and precursor m/z values were consistent across all laboratories.
Seven of the laboratories used 4000 QTRAP mass spectrometer instruments; the eighth site
used a ThermoFisher TSQ Quantum Ultra triple quadrupole. Each laboratory tested and, if
necessary, further optimized instrument parameters to maximize MS responses for the
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selected fragment ions on individual instruments. For the TSQ Quantum Ultra instrument,
not all preselected transitions were ideal for achieving maximum sensitivity. For this subset
of peptides, the site selected and optimized a substitute MRM transition for the signature
peptide and its corresponding isotopically labeled analog (Supplementary Table 1b). Peptide
YEVQGEVFTKPQLWP from C-reactive protein (CRP)-YEV did not ionize well and was
detected with very low signals in the tuning mixtures or in the QC samples circulated to
each site. Although MRM transitions for this peptide were included for data acquisition,
subsequent data were not analyzed.
Intralaboratory reproducibility and precision of MRM assays
Intralaboratory variability and reproducibility in studies I–III were evaluated by comparing
the measured concentrations to the actual concentrations across the range of spiked-in
analytes and determining the coefficient of variation (CV) for these quantitative
measurements. Figure 2a shows measured log concentration (y axis) versus theoretical
(spiked-in) concentration (x axis) for the SSDLVALSGGHTFGK peptide derived from
horseradish peroxidase (HRP-SSD; for all other peptides, Supplementary Fig. 1). Data for
each site are color-coded, and organized by study and concentration. A linear trend is
observed in the measured concentrations for studies I–III as spiked-in analytes increase
across the concentration range. However, measured concentrations decrease as laboratories
progress from study I to II to III. This trend is a result of apparent peptide loss from
incomplete digestion of HRP protein and variability in sample handling at each site, as study
complexity was increased (Fig. 1). Study I represents the optimum assay performance, as
synthetic peptides (not proteins) were used as analytes. Protein digestion in study II (at a
central location in the absence of plasma) and study III (at individual sites and in the
presence of plasma) introduces potential sources of sample loss that decrease analyte
recovery and reduce measured concentrations for studies II and III.
Intralaboratory CVs for studies I and II constitute a measure of the technical variation due to
instrument and data acquisition, as all sample preparation was performed centrally. The
intralaboratory CVs at each analyte concentration point are shown in Figure 2b for the HRP-
SSD peptide with color coded markers representing individual laboratories. Equivalent
figures for all other peptides are shown in Supplementary Figures 2 and 3. Table 2
summarizes the range of median intralaboratory CVs observed across studies I, II and III,
and Supplementary Table 2a–c shows the intralaboratory CVs calculated for each analyte at
each of the nine final concentrations in plasma. Intralaboratory CVs are color coded in
Supplementary Table 2a–c to facilitate visualization of the increasing variability from
studies I–III. For all ten peptides in study I, median intralaboratory CVs were ≤15% across
the concentration range (Supplementary Fig. 1 and Supplementary Table 2a). The median
intralaboratory CVs for study II were very similar to those found in study I, with most
intralaboratory CVs ≤15% across the concentration range (Supplementary Fig. 1 and
Supplementary Table 2b). Finally, the intralaboratory CVs for study III were a measure of
variation of the sample processing across replicates in addition to the technical variation of
data acquisition. Increased variability is observed across the laboratories as individual sites
were responsible for all sample handling and preparation (Fig. 2b). Although the
intralaboratory CVs were elevated relative to studies I and II, >60% of the median
intralaboratory CVs were still ≤25% across all concentrations, demonstrating very good
reproducibility for sample processing (Supplementary Fig. 1 and Supplementary Table 2c).
Interlaboratory reproducibility and precision of MRM assays
The interlaboratory reproducibility and precision of the quantitative measurements was
evaluated by calculating the CV of the quadruplicate analyses at each of the nine final
analyte concentrations in plasma. The median interlaboratory CVs for HRP-SSD across
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studies I, II and III for the entire concentration range of 1–500 fmol/µl were predominantly
≤15% for this peptide in all three studies (Fig. 2b). As expected, interlaboratory CVs
decreased as the concentration of spiked-in analyte increased to the upper range (Fig. 2b).
However, even at lower analyte concentrations, the precision of the quantitative
measurements across sites was very good. Table 2 summarizes the interlaboratory CVs at
the 2.92 fmol/µl concentration for all peptides. This concentration is at or near the limit of
quantification (LOQ) for most analytes in diluted plasma, except the two peptides derived
from CRP (see below). Box plots of median interlaboratory CVs for all other peptides are
shown in Supplementary Figure 2 (comparison of CVs across studies I, II and III) and
Supplementary Figure 3 (comparison of CVs across process replicates for studies IIIa, IIIb
and IIIc).
For study I, the interlaboratory CVs ranged from 4.3 to 14.1% at 2.92 fmol/µL, with eight of
ten peptides in excellent agreement with values ≤ 10%. Because the interlaboratory CVs
decreased at higher analyte concentrations, the median interlaboratory CVs across the entire
concentration range was ≤5% (Supplementary Fig. 2 and Supplementary Table 2a). These
results demonstrate excellent precision and reproducibility of the MRM assays for the
signature peptides between laboratories when the major analytical variable is limited to the
LC-MS system. Study II introduced new sources of variability attributable to sample loss
during reduction, alkylation and trypsin digestion of the target proteins and desalting of the
resulting peptide mixtures (Fig. 1 and Online Methods). The median interlaboratory CVs at
2.92 fmol/µl for study II ranged from 3.8% to 30% for all peptides, with nine of ten peptides
having interlaboratory CVs ≤ 15%. Median interlaboratory CVs were predominantly ≤ 10%
over the entire concentration range for study II (Supplementary Fig. 2 and Supplementary
Table 2b), indicating that reproducibility of the assay across sites was not hampered by
decreased recovery of target peptides. Finally, study III introduced the potential for the
largest variability as each of the laboratories reduced, alkylated and trypsin digested the
target proteins in plasma and desalted the subsequent peptide mixtures in three process
replicates. Despite these additional sources of variability, average interlaboratory CVs for
study III across process replicates IIIa, IIIb and IIIc ranged from 10.3–50% at 2.92 fmol/µl
for nine of ten peptides (Table 2). Eight peptides had interlaboratory CVs ≤25%. Across the
concentration range, the median interlaboratory CV was predominantly ≤20%
(Supplementary Fig. 2 and Supplementary Table 2c).
Limits of detection and quantification
For studies I and II, inter- and intralaboratory measurement reproducibility of the ten
signature peptides was determined at their estimated limits of detection (LOD)
(Supplementary Fig. 4) and LOQ (Fig. 2c). The LOQ values represented in the box plot are
based on the amount of peptide (in fmol) detected in plasma that was diluted 60-fold to a
final protein concentration of 1 µg/µl for SID-MRM-MS analysis. The corresponding LOQ
values for measurement of the proteins in undiluted plasma (in mg/ml) were also calculated
(Fig. 2c). LOD and LOQ values calculated for each peptide at each site are shown in
Supplementary Table 3.
The reproducibility of the LOQ estimations across sites was very good. For example, in
study I, eight of ten peptides had median LOQ values between 0.66 and 2.0 fmol/µl when
peptides were added into 1:60 diluted plasma (equivalent to a range of 0.70–3.34 µg/ml
protein in plasma; Fig. 2c). The remaining two CRP peptides were detected at endogenous
levels in the blank and 0 fmol/µl spiked plasma samples. A commercial enzyme-linked
immunosorbent assay (ELISA) was performed on the plasma stock and yielded a
concentration of 6 µg/ml of this protein (data not shown), which is equivalent to 4 fmol/µl of
CRP in the diluted plasma. The LOQ values obtained in study II, which were similar to
those obtained in study I, ranged between 0.31 and 1.8 fmol/µl for the same eight of ten
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peptides. The LOD/LOQ values for studies I and II were similar in magnitude for a majority
of the signature peptides and showed acceptable variation across all eight laboratories.
Reproducibility of linear response and peptide recovery
Figure 3 shows a compilation of response curves (study II) obtained at the eight sites and
plotted on a linear-linear scale for the HRP-SSD peptide. Response curves are plots of
experimentally determined concentrations versus theoretical concentrations of the target
analyte, and provide useful visual representations of reproducibility and linearity.
Quadruplicate replicates are shown at every concentration for all three MRM transitions.
Interlaboratory reproducibility of linear responses and quantitative measurements across all
laboratories and all three studies was, in general, very good (Table 2). The fitted slopes
presented in Table 2 demonstrate the consistency in the linear response with a change in
actual peptide (study I) or protein (studies II–III) concentration across the measurements
made in each laboratory, and are also an estimation of peptide recovery. A slope of 1.0 is
equal to the theoretical slope in which measured concentration is proportional to analyte
concentration and recovery is equal to 100%. Slopes <1 indicate <100% recovery, whereas
slopes >1 indicate >100% recovery (the latter likely a result of errors in the initial
concentrations of the peptide or protein stock solutions). For the representative peptide,
HRP-SSD, the average slope in study I was 1.2 with an interlaboratory CV of 15.6% (Table
2 and Supplementary Table 4a), showing excellent reproducibility between sites and highly
consistent linear responses across laboratories and instrument platforms as indicated by the
slopes being close to the theoretical line. As an estimation of the average percent recovery
across the concentration range, the average slope for the HRP-SSD peptide agrees well with
the calculation of percent recovery determined at the mid-concentration point of the
response curve (46 fmol/µl; Table 2).
Response curves for all other peptides and proteins generated by each laboratory in all three
studies are plotted on the linear-linear scale with scale-expansion insets to facilitate
visualization of the lower concentration range (Supplementary Fig. 5). A weighted robust
linear regression on the linear-linear scale was used to determine slope and percent recovery.
In addition, the response curves are plotted on the log-log scale (Supplementary Appendix)
without regression lines to facilitate data visualization. Individual parameters for slope, y
intercept and their associated standard errors for each peptide across all sites are shown in
Supplementary Tables 4a–e. Altogether, peptide responses in study I had an average slope
ranging from 1.1 to 1.6 with an interlaboratory CV ≤ 10% for most of the peptides (Table 2
and Supplementary Tables 4a). The average slope value was more variable in study II, with
a range of 0.15 to 1.5 across all peptides. Interlaboratory CV for slope in study II was ≤15%
for nine of ten peptides (Supplementary Table 4b). Study III exhibited the lowest average
slope values, which ranged from 0.16 to 0.92 for nine of ten peptides, and interlaboratory
CVs for slope were ≤25% for the majority of peptides across the process replicates
(Supplementary Table 4c–e). One peptide, MBP-YLA, was not detected by any site in any
process replicate of study III. Overall, the responses were reproducible as indicated by the
low interlaboratory CVs, and the measurements of the three transitions were highly uniform
such that the replicates often overlaid at each concentration (Fig. 3 and Supplementary Fig.
5).
Because the slope is an estimation of percentage recovery, the decrease and variability in the
slopes of the response curves observed across these studies (Supplementary Fig. 6) correlate
with the increasing level of sequential experimental complexity, from the introduction of
protein digestion in study II and protein digestion in the presence of plasma in study III (Fig.
1). Again, the average slopes for all peptides agree well with the calculation of percent
recovery at the mid-point of the concentration range (Table 2). For study I and two of the ten
peptides in study II, recovery ≥100% was observed for many peptides. This could most
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likely be attributed to the effect of errors in quantification of the protein or peptide stock
concentrations by amino acid analysis, and inaccuracies associated with sample preparation,
such as pipetting and freeze-thawing. In study III, six of the nine peptides detected had
percent recoveries ≥40%, which is within an acceptable range for verification assays2,9.
Four peptides (CRP-GYS, LEP-IND, MBP-HGF and MBP-YLA) had recoveries ≤25%, and
would not be considered useable for verification or clinical validation assay purposes. No
significant differences in peptide recovery were observed across the concentration range or
between studies II and III (Supplementary Table 5 for two representative examples).
Although <100% recovery of the target peptides limits the sensitivity of the assays, these
results show very good reproducibility for recovery of most peptides and demonstrate the
large role sample handling has in the variability of peptide recovery.
Common sources of variance and their detection
Although most of the signature peptides exhibited excellent reproducibility within and
between laboratories (Supplementary Fig. 5), deviations from the trend lines were observed
for some peptides at one or more sites. Typical problems that can arise in developing and
applying MRM assays to quantify proteins in plasma are illustrated in Figure 4. The most
common problem related to the appearance of ‘outliers’ was interference in one or more of
the fragment-ion transitions monitored for either the light (12C/14N) peptides or heavy
(13C/15N)-labeled internal standard peptides. Figure 4a,b illustrates interferences in
transition 1 and 2 of the light peptides for MBP-HGF and MYO-LFT, respectively, at two
analysis laboratories. In both cases, the relative ratios of the transitions were altered from
those observed in the absence of plasma during assay configuration, resulting in
considerable deviation from linearity for the respective product ions. Monitoring multiple
transitions for each peptide, as done in our study, enables reliable quantification, which is
accomplished by using the other unaffected transitions. In the case of CRP-ESD (Fig. 4c),
obvious and highly consistent deviation from linearity was observed for all three transitions
monitored at the lower end of the response curves. This flattening of the curves was due to
the presence of endogenous levels of the protein within the measurable range of the MRM
assays. We confirmed the level of CRP present in the plasma by ELISA. Other issues, such
as unstable electrospray conditions, lack of recovery during sample processing and
saturation of the MS detector were also observed and gave rise to recognizable patterns of
misbehavior (Fig. 4d–f). Instability of the LC system and deterioration of the LC column are
also common problems that are readily recognized. If not corrected, they can cause large
shifts in peptide retention time and chromatographic peak broadening or tailing, particularly
for early-eluting hydrophilic species, resulting in decreased reproducibility for peptide
detection and quantification.
DISCUSSION
Targeted MRM assays have been used very successfully for quantifying small molecules
(e.g., hormones, drugs and their metabolites) in pharmaceutical research and in clinical
laboratories in applications such as screening newborns for disease11. More recently, the
merits of SID-MRM-MS for quantifying peptides derived from proteins in plasma have been
demonstrated in several laboratories4–9,12. These studies have, however, only addressed
assay performance at a single laboratory, and thus were not able to demonstrate the multisite
robustness needed in large-scale biomarker research and ultimately in preclinical and
clinical applications. The main purpose of this study was to provide such a demonstration by
performing an assessment of the analytical characteristics of a multiplexed, SID-MRM-MS
assay across eight laboratories using seven target proteins with which to spike human
plasma. A three-tiered experimental protocol was used that progressively introduced sample
preparation variables likely to affect inter- and intralaboratory reproducibility,
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transferability, precision and sensitivity. Our results demonstrate that reproducible,
quantitative measurements of proteins in plasma can be made by SID-MRM-MS in multiple
laboratories using different instrument platforms through use of standardized protocols for
sample preparation, data acquisition and data analysis. The robustness of such a targeted
assay approach compensates for the greater variability in protein measurements inherent in
shotgun (‘discovery’ proteomics) methods13,14, enabling the development of an effective
biomarker pipeline1.
Reproducibility and precision of the quantitative measurements for nine of ten peptides
tested across eight laboratories ranged from 4–14%, 4–13% and 10–23% interlaboratory
CVs at or near the estimated LOQ for study I, II and III, respectively. Intralaboratory CVs
were predominantly <15% and <25% at the identical concentration for studies I/II and III,
respectively (Supplementary Table 2). Although the current assay performance under real
biomarker conditions (study III) is below that generally stated for clinical assays (typically
<10–15%), the performance achieved is sufficient for the verification of candidate
biomarkers2 present at more than ~2–6 µg/ml in plasma, with a linear dynamic range
spanning three orders of magnitude. In all cases, interlaboratory and intralaboratory CVs
improved with increasing analyte concentration. Such modest differences between
interlaboratory and intralaboratory CVs underscore the excellent agreement between the
eight participating laboratories. Likewise, the progressive increases in CVs from studies I to
III indicate convincingly that sample preparation contributes more to assay variability than
instrumental variability, further highlighting the data quality obtainable from SID-MRM-
MS. Although most important parameters were governed by detailed SOPs, the transfer of
MRM assays across LC-MS platforms did require optimization of the transitions being
monitored to compensate for differing instrument-specific ion source and collision-induced
dissociation parameters, and to ensure that each platform achieved optimum sensitivity
(Supplementary Tables 1a–e). Despite these variations concerning a small number of analyte
peptides, interlaboratory variability and specificity of the assay were not affected (Table 2).
Differences emerged in assay performance for different peptides. Most peptides performed
well at all eight sites, whereas a few exhibited variable or poor behavior. This result
highlights the dependence of MRM assay performance in plasma on specific properties of
the peptides selected as surrogates for the target proteins. Ideally the final selection of
signature peptides for SID-MRM-MS biomarker assays should be based on multisite studies
so as to ensure the most robust performance.
The most frequent cause of poor peptide performance was the presence of interference from
the background plasma digest matrix, in either the analyte or internal-standard channels,
which altered the ratios of these transitions. Monitoring a minimum of three transitions per
analyte is critical in maintaining assay selectivity and recognizing such interferences when
they occur. Most participating sites observed interferences in one or more peptides over the
course of the three studies. In the case of CRP, we were able to establish that the flattening
of the response curves was due to the presence of endogenous levels of CRP as all three
transitions monitored were affected equally and the expected ratios of the transition-ion
abundances to one another were maintained. Other interferences arose from problems with
chromatography (e.g., large peak widths, shifting retentions times, or early elution and
consequent sensitivity to intermittent or unstable electrospray conditions), which can be
addressed by further refinement of protocols, particularly in LC operation and data
acquisition.
Recovery of signature peptides generally decreased from study I to III, as proteolytic
digestion and subsequent sample handling, such as desalting, were introduced into the
experimental workflow. Digestion efficiency of proteins in the plasma matrix has only
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recently begun to be studied15. If a signature peptide is not detected in an MRM assay, it is
often unclear if this is because of (i) losses from sample handling, such as fractionation or
desalting, (ii) poor enzymatic digestion, (iii) concentration below LOD, (iv) post-
translational modification such as glycosylation and phosphorylation, (v) artifactual
modifications to reactive amino acids, such as oxidation or carbamylation, or (vi) some
combination thereof. The effect of decreasing control of sample preparation was reflected in
the increased variability and lower peptide recoveries for a majority of peptides as sites
progressed from study II to III (Table 2 and Supplementary Fig. 6). In study III, one peptide
was not recovered in any process replicate performed at all participating laboratories, and
four peptides had <25% recovery (Table 2 and Supplementary Fig. 6). Addition of labeled
internal standard (IS) peptides at an early stage in sample processing (e.g., during enzymatic
digestion) could help to account for peptide loss. However, lower recovery of signature
peptides does not impede the use of these assays for verification where the goal is to
precisely define the relative difference in abundance for candidate proteins between cases
and controls rather than to determine the absolute concentration of each protein. Absent a
general method ensuring stoichiometric digestion, absolute concentration measurements
would likely require addition of isotopically labeled, recombinant protein standards at the
start of sample processing.
The purpose of the present study was not to define the ultimate sensitivity possible for
proteins by SID-MRM-MS, but rather to evaluate the transferability and robustness of the
technology within and between laboratories. For this first study, we made no attempt to
reduce the complexity of the plasma matrix by either depletion of abundant proteins or
fractionation. The sensitivity of protein quantification by SID-MRM-MS in plasma is
severely limited by the complexity and 1011 dynamic range of protein abundances in blood,
and the susceptibility to interference from other peptides and their fragment ions is greatest
in this matrix16. Typical LODs and LOQs observed in prior studies of unfractionated plasma
are in the high 100s of ng/ml to low µg/ml range of target protein6,8,17. Results described
here are consistent with these reports across sites and instrument platforms (Fig. 2c and
Supplementary Fig. 4). Although emphasis is often placed on discovery and verification of
low-abundance candidate biomarkers (≤ ng/ml levels in serum), high-abundance serum
proteins, such as CRP, transferrin, complement components, immunoglobulin classes and
lipoproteins, are clinically relevant markers of disease and their levels in blood make them
directly accessible by SID-MRM-MS using the approaches described here. The LODs and
LOQs of MS-based assays have been extended into the low ng/ml range in plasma by using
immunoaffinity depletion of high-abundance proteins, limited protein or peptide
fractionation, or immunoaffinity enrichment at the protein or peptide level before SID-
MRM-MS9,17–24. The additional processing steps used are likely to introduce new sources
of experimental variation that will have to be assessed in interlaboratory studies similar to
those described here. Nevertheless, the assay performance reported in the present studies,
measured at maximum levels of interfering high-abundance peptides in unfractionated
plasma digests, suggests that similar or better intra- and interlaboratory assay performance
may be achievable for quantitative, multiplexed measurement of proteins in the low ng/ml
range in plasma by MS.
Our study demonstrates that targeted, quantitative and multiplexed MS-based assays can be
rapidly configured and deployed in multiple laboratories to yield robust and reproducible
assays for proteins down to low µg/ml levels in the context of unfractionated plasma. This is
a critical first step toward potential widespread implementation of SID-MRM-MS assays for
verification of novel protein biomarker candidates. The SID-MRM-MS technology has the
potential to become the critical filter used to assess candidate biomarker performance in a
sufficient number of patient samples before committing the very substantial time and
resources required to create clinical-grade immunoassays. The performance required of such
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assays2 is not as stringent as that currently required for US Food and Drug Administration–
approved clinical assays25. Beyond candidate verification, SID-MRM-MS assays may
eventually have potential to replace certain clinical immunoassays, especially in cases where
interferences are known to exist23 or multiplex measurements are needed. By detecting a
structural component of the protein, the signature peptide, with near-absolute structural
specificity, SID-MRM-MS should avoid inter-assay differences that occur when different
immunoassays for the same protein detect distinct, potentially labile epitopes. Furthermore,
the simplicity of producing and characterizing peptide-based reference materials for SID-
MRM-MS could help overcome well-known problems with ELISA assay standardization,
which lead to varying results across multiple clinical laboratories26,27.
The methods, reagents and multilaboratory data sets presented here should facilitate testing
and implementation of MRM-based multiplex assays for quantifying target proteins in
plasma by the proteomics community. Our results should foster greater acceptance by the
clinical community of SID-MRM-MS technology as a generally applicable approach to
verify candidate biomarkers in large clinical sample sets, and thus provide a critical
component for a systematic biomarker-development pipeline.
METHODS
Methods and any associated references are available in the online version of the paper at
http://www.nature.com/naturebiotechnology/.
Data accession
A password-protected website was developed to manage the large number of data files
generated for the described interlaboratory studies. This website, hosted at NIST, was
designed as a portal used by the teams for initiating uploads and downloads of large data
files. The data transfers were performed using Tranche (http://trancheproject.org/) an open
source, secure peer-to-peer file-sharing tool. A customized user interface employed by the
participating laboratories was developed and added to the Tranche code base. This tool
allowed the website and database to communicate tracking information with Tranche by
employing custom URLs. The Tranche hash (a unique data identifier) and pass-phrase, for
each website, was automatically recorded into the website’s database when file uploading
was complete. These stored links allow subsequent retrieval of data files using the Tranche
download tool. The Tranche hashes and passphrases provide a simple and portable
mechanism to access data sets and can be easily associated with supporting annotation. The
data associated with this manuscript may be downloaded from the ProteomeCommons.org
Tranche network using the following hash: CKpfN0bl2ULLwCaIovXn/spuw4rYfJF6H/L+/
6sHAKGzCsj4fzTD0Rau JjAwf9baB8tI36HQ0izji2tupYAPM29P2cAAAAAAAT0iw==.
The hash may be used to show exactly what files were published as part of this manuscript’s
data set, and the hash may also be used to check that the data have not changed since
publication. Accessible information includes all raw data files, all processed data export
files, 4000 QTRAP MultiQuant results files, as well as detailed data submission sheets and
file annotation legends for studies I–III from the eight participating laboratories.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Sample preparation workflow for studies I, II and III. (a) Study I. Pooled, digested plasma
was spiked with 12C and 13C/15N peptides to generate a nine-point standard curve. (b) Study
II. An equimolar mixture of the seven target proteins was digested separately and spiked
with an equimolar mixture of IS peptides. The digest of target proteins plus IS peptides was
added to pooled, digested plasma. A nine-point standard curve was prepared with pooled,
digested plasma spiked with an equimolar mixture of IS peptides as the diluent. Study I and
study II samples were prepared centrally at NIST. (c) Study III. Undiluted plasma was
spiked with an equimolar mixture of the target proteins, then diluted with plasma to generate
a nine-point standard curve. Three aliquots of these samples (prepared at NIST) were then
shipped to the eight participating sites where reduction, alkylation, digestion and desalting
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were carried out before SID-MRM-MS analysis. IS, internal standard; SPE, solid phase
extraction.
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Box plots of variation in MRM quantitative measurements, interlaboratory CV,
intralaboratory CV and LOQ. (a) Intralaboratory assay CV. Box plots showing measured log
concentration (y axis) versus theoretical (spiked-in) concentration (x axis) for HRP-SSD
across the entire concentration range in diluted plasma. Protein concentration in µg/ml is mg
protein equivalent in 1 ml undiluted plasma. The box plots for studies I and II are based on
four replicate measurements, whereas those for study III summarize 12 measurements (four
each from III a, b and c). Each of the eight sites was assigned a random numerical code (19,
52, 54, 56, 65, 73, 86, 95) for anonymization. (b) Interlaboratory assay CV. Values are
shown for studies I–III for the entire range of HRP-SSD final analyte concentrations in
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plasma. Within each box plot, actual intralaboratory CV values for individual laboratories
are shown with color-coded markers. The CV values are calculated based on the single best
performing transition (lowest combined CV) across studies I and II. This same transition is
also used for study III. (c) Interlaboratory assay LOQ. Values determined in studies I and II
for the peptides indicated (see Table 1 for protein-peptide pair abbreviations). The inset
values display the conversion of median LOQ to µg/ml (µg protein equivalent per 1 ml
undiluted plasma) for each peptide. All measurements were made in 60-fold diluted plasma.
Median is shown as a heavy horizontal line in all box plots. The box spans the interquartile
range (IQR), with the whiskers extending to 1.5 × IQR. Values > 1.5 × IQR are deemed
outliers, and shown as separate points.
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Interlaboratory reproducibility of linear calibration curve slopes for study II. The eight plots
display the concentration curves for the detection of HRP-SSD in study II across all
laboratories. Each of the eight sites was assigned a random numerical code (19, 52, 54, 56,
65, 73, 86, 95) for anonymization. Comparison of the plots demonstrates good linearity,
with the slopes falling close to the diagonal, black line (theoretical slope = 1), and good
agreement between the three transitions at each concentration point. Four replicate
measurements are represented at each concentration point. Analyte transitions: red diamond,
transition 1, (m/z 492.6→703.4); blue asterisk, transition 2, (m/z 492.6→790.4); green
triangle, transition 3, (m/z 492.6→974.5). In some cases, the data points overlay such that
transition 1 is not visible. Inset plots show more detail of lower end of the concentration
range. The mean slope calculation across all laboratories in this example is 0.794 with an
interlaboratory CV of 18.7%. Final concentrations of heavy and light peptides and added
proteins were adjusted according to the gravimetric measurements described in
Supplementary Table 6a–f.
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Response curves representing deviations from the trend line. Red diamond, transition 1; blue
asterisk, transition 2; green triangle, transition 3. (a) Study I, site 52, MBP-HGF:
interference in transition 1 of the analyte. (b) Study IIIb, site 95, MYO-LFT: interference in
transition 2 of the analyte, which was also observed in study I, II and IIIa for this laboratory.
(c) Study II, site 86, CRP-ESD: endogenous protein level increased the estimated protein
concentration at the low end of the concentration range of spiked-in proteins, resulting in
flattening of slope. (d) Study IIIa, site 56, LEP-IND: unstable electrospray conditions
resulted in a substantial increase in interlaboratory CV to 99%. (e) Study IIIa, site 19, MBP-
YLA: no detection of MBP-YLA peptide at any site. (f) Study I, site 86, PSA-IVG:
saturation at highest two concentrations. Site codes are identical to those given in Figures 2
and 3.
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